Assessment of Different Niosome Formulations for Optogenetic Applications: Morphological and Electrophysiological Effects
Ikusi/ Ireki
Data
2023-07-01Egilea
Celdrán, José David
Humphreys, Lawrence
González, Desirée
Soto-Sánchez, Cristina
Martínez-Navarrete, Gema
Maldonado Pérez, Iván
Gallego Garrido, Idoia
Villate Beitia, Ane Ilia
Sainz Ramos, Myriam
Puras Ochoa, Gustavo
Fernández, Eduardo
Pharmaceutics 15(7) : (2023) // Article ID 1860
Laburpena
Gene therapy and optogenetics are becoming promising tools for treating several nervous system pathologies. Currently, most of these approaches use viral vectors to transport the genetic material inside the cells, but viruses present some potential risks, such as marked immunogenicity, insertional mutagenesis, and limited insert gene size. In this framework, non-viral nanoparticles, such as niosomes, are emerging as possible alternative tools to deliver genetic material, avoiding the aforementioned problems. To determine their suitability as vectors for optogenetic therapies in this work, we tested three different niosome formulations combined with three optogenetic plasmids in rat cortical neurons in vitro. All niosomes tested successfully expressed optogenetic channels, which were dependent on the ratio of niosome to plasmid, with higher concentrations yielding higher expression rates. However, we found changes in the dendritic morphology and electrophysiological properties of transfected cells, especially when we used higher concentrations of niosomes. Our results highlight the potential use of niosomes for optogenetic applications and suggest that special care must be taken to achieve an optimal balance of niosomes and nucleic acids to achieve the therapeutic effects envisioned by these technologies.
Collections
Bestelakorik adierazi ezean, itemaren baimena horrela deskribatzen da:© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).